These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Secondary prevention of ischemic cardiopathy with anti-platelet aggregates in the post-infarct patient. Review]. Verdecchia P G Ital Cardiol; 1982; 12(8):598-603. PubMed ID: 6762978 [No Abstract] [Full Text] [Related]
3. Secondary prevention of myocardial infarction. Davies JA Int J Clin Pharmacol Res; 1985; 5(5):303-7. PubMed ID: 3905632 [TBL] [Abstract][Full Text] [Related]
4. Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. Turpie AG Prog Clin Biol Res; 1982; 89():31-62. PubMed ID: 7051035 [TBL] [Abstract][Full Text] [Related]
5. Role of platelet-active drugs in coronary artery disease. Sherry S Cardiovasc Clin; 1983; 14(1):173-89. PubMed ID: 6352025 [No Abstract] [Full Text] [Related]
6. [Platelet antiaggregants in the treatment of arterial thrombosis]. Ferlito S Minerva Cardioangiol; 1991 Oct; 39(10):375-89. PubMed ID: 1803283 [TBL] [Abstract][Full Text] [Related]
7. [Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies]. Shalaev SV Kardiologiia; 1989 Sep; 29(9):116-20. PubMed ID: 2687554 [No Abstract] [Full Text] [Related]
13. [Long-term antithrombotic treatment in coronary disease]. Hodara M; Samama M J Mal Vasc; 1983; 8(1):28-32. PubMed ID: 6405004 [TBL] [Abstract][Full Text] [Related]
14. [Aftercare of heart infarct patients to reduce the risk of a subsequent infarction]. Offerhaus L Ned Tijdschr Geneeskd; 1983 Apr; 127(16):673-9. PubMed ID: 6134240 [No Abstract] [Full Text] [Related]
15. [Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics]. Schröder R Dtsch Med Wochenschr; 1981 Apr; 106(17):546-53. PubMed ID: 6111439 [No Abstract] [Full Text] [Related]
16. Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts). Genton E; Gent M; Hirsh J; Harker LA N Engl J Med; 1975 Dec; 293(23):1174-8. PubMed ID: 1102977 [No Abstract] [Full Text] [Related]
17. [Prophylactic value of platelet anti-aggregants in coronary disease]. Verstraete M Clin Ter; 1979 Oct; 91(2):117-27. PubMed ID: 396098 [No Abstract] [Full Text] [Related]
18. Critical evaluation of platelet-inhibiting drugs in thrombotic disease. Harker LA; Hirsh J; Gent M; Genton E Prog Hematol; 1975; 9():229-54. PubMed ID: 766074 [No Abstract] [Full Text] [Related]
19. [Clinical application and evaluation of anti-platelet agents]. Yasunaga K Nihon Rinsho; 1978 Dec; 36(12):3884-94. PubMed ID: 372628 [No Abstract] [Full Text] [Related]
20. A critical appraisal of the clinical efficiency of anti-platelet drugs. Lecompte T; Samama M Agents Actions Suppl; 1986; 20():203-14. PubMed ID: 3544741 [No Abstract] [Full Text] [Related] [Next] [New Search]